30 likes | 51 Views
CMOAPI has a full range of raw materials of lorcaserin , and has a total quality management system.Also passed GMP and DMF certification. Visit: https://www.cmoapi.com/our-products/lorcaserin/<br>
E N D
Who can and can’t take Lorcaserin? Who can take Lorcaserin? Lorcaserin, marketed under the brand name Belviq is a weight-loss drug developed . It reduces appetite by activating a type of serotonin receptor known as the 5-HT2C receptor in a region of the brain called the hypothalamus, which is known to control appetite. Lorcaserin powder is specifically indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in clinically obese adults (BMI of 30 kg/m2 or greater) and overweight adults (BMI of 27 kg/m2 or greater) with at least one weight-related comorbid condition.To maintain weight loss long-term, you’ll have to make permanent changes to your diet and exercise habits. Like all weight loss medications, lorcaserin powder is only recommended under the supervision of your obesity medicine doctor. Who can not take lorcaserin? Do not use lorcaserin if you are pregnant. Weight loss during pregnancy can harm an unborn baby, even if you are overweight. Tell your doctor right away if you become pregnant during
treatment.Also lorcaserin is not approved for use by anyone younger than 18 years old. To make sure lorcaserin is safe for you, tell your doctor if you have: diabetes; congestive heart failure; a heart valve disorder; a heart condition such as "AV block" (2nd or 3rd degree); sickle cell anemia; leukemia or myeloma; kidney or liver disease; or a physical deformity of the penis (such as Peyronie's disease). It is not known whether lorcaserin passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine. Reference 1. Wilson MR (19 December 2012). "Reg Watch". The Hill. Archived from the original on 20 March 2013. 2. "Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV". 19 December 2012.
3."Department Of Justice Drug Enforcement Administration 21 CFR Part 1308, Placement of Lorcaserin into Schedule IV". 8 May 2013. 4. Greenway FL, Shanahan W, Fain R, Ma T, Rubino D (October 2016). "Safety and tolerability review of lorcaserin in clinical trials". Clinical Obesity (Review). 6 (5): 285–95. doi:10.1111/cob.12159. PMID 27627785. 5. "BELVIQ and BELVIQ XR HCP Home Page". www.belviqhcp.com. Archived from the original on 16 June 2016. https://www.cmoapi.com/ https://www.cmoapi.com/our-products/lorcaserin/ https://www.facebook.com/Cmoapi-114510347044359/ https://www.pinterest.com/cmoapibiotech/boards/ https://sites.google.com/view/cmoapi-lorcaserin-for-sell/